Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hehe Shuyangfang Granules is a Traditional Chinese Medicine (TCM) formulation developed by the Guangdong Provincial Hospital of Chinese Medicine. It is primarily indicated for the treatment of chronic hepatitis B (CHB) and early-stage liver fibrosis. The formulation is typically administered orally and is often evaluated in clinical trials as part of a combination regimen with other TCM products, such as Anluo Huaxian Pills. Hehe Shuyangfang Granules is designed to improve liver function, reduce liver stiffness, and manage symptoms associated with chronic viral hepatitis through a multi-component approach based on TCM principles of syndrome differentiation. Clinical studies have focused on its efficacy in preventing the progression of liver fibrosis and improving the overall quality of life for patients with CHB.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hehe Shuyangfang Granules.